chr1-102888730-C-A
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The ENST00000370096.9(COL11A1):c.4547G>T(p.Gly1516Val) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G1516D) has been classified as Likely pathogenic.
Frequency
Consequence
ENST00000370096.9 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COL11A1 | NM_001854.4 | c.4547G>T | p.Gly1516Val | missense_variant | 61/67 | ENST00000370096.9 | NP_001845.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COL11A1 | ENST00000370096.9 | c.4547G>T | p.Gly1516Val | missense_variant | 61/67 | 1 | NM_001854.4 | ENSP00000359114 | P1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 38
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Marshall syndrome;C1858084:Stickler syndrome type 2;C4760307:Hearing loss, autosomal dominant 37 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Center of Genomic medicine, Geneva, University Hospital of Geneva | Sep 11, 2020 | - - |
COL11A1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 26, 2024 | The COL11A1 c.4547G>T variant is predicted to result in the amino acid substitution p.Gly1516Val. This variant has been reported in two individuals with Marshall/Stickler syndrome/isolated hearing loss (reported as G988V; Annunen et al. 1999. PubMed ID: 10486316; reported as de novo, Van Heurck et al. 2021. PubMed ID: 34440452). This variant affects a Gly residue of the conserved Gly-Xaa-Yaa triple helical domain (amino acid residues 529-1542, www.uniprot.org/uniprotkb/P12107/), where substitutions of glycine are usually pathogenic (Richards et al. 2010. PubMed ID: 20513134; https://www.ncbi.nlm.nih.gov/books/NBK1302/). This variant has not been reported in a large population database, indicating it is rare. This variant is interpreted as pathogenic. - |
Marshall syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Center For Human Genetics And Laboratory Diagnostics, Dr. Klein, Dr. Rost And Colleagues | Nov 09, 2017 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jul 23, 2018 | - - |
Stickler syndrome type 2 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | DASA | Feb 05, 2022 | The c.4547G>T;p.(Gly1516Val) missense variant has been observed in affected individual(s) and ClinVar contains an entry for this variant (PMID: 20513134) - PS4_supporting. The variant is located in a mutational hot spot and/or critical and well-established functional domain (collagen helix of α1(XI) collagen) - PM1. This variant is not present in population databases (rs1553193910; gnomAD; ABraOM no frequency - http://abraom.ib.usp.br/) - PM2. Multiple lines of computational evidence support a deleterious effect on the gene or gene product - PP3. In summary, the currently available evidence indicates that the variant is likely pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at